The Cystic Fibrosis Foundation awarded up to $5 million to Armata Pharmaceuticals for the first-ever controlled clinical study of phage therapy in CF, reaffirming the Foundation's commitment to advance innovative solutions to the growing challenge of antibiotic resistance.
Site Search
Corbus Pharmaceuticals reported today that the Phase 2b clinical trial of its potential anti-inflammatory drug lenabasum did not meet its primary objective of decreasing pulmonary exacerbations in people with cystic fibrosis.
Today, Vertex Pharmaceuticals Inc. announced positive Phase 3 clinical trial data for Trikafta® (elexacaftor/tezacaftor/ivacaftor) in children 6-11 years old with cystic fibrosis.
The Cystic Fibrosis Foundation would like to thank New York Giants placekicker Josh Brown and Tommy Bahama for their efforts in supporting the search for a cure for cystic fibrosis.
The Cystic Fibrosis Foundation has launched a new program that will fund 60 additional research coordinators to help speed the progress of CF clinical trials throughout its Therapeutics Development Network (TDN).
It was the year of 1957 when Phyllis Kossoff, one of the earliest volunteers of the Cystic Fibrosis Foundation and mother of a child with CF, found herself standing before a room of women, asking for help.
Tommy Danger didn't know it then, but the day his best friend's son was born was the day Tommy's life changed forever.
Comedian and longtime friend of the Cystic Fibrosis Foundation, Lewis Black, brought together some of the biggest names in the entertainment business for a variety show that benefited the Cystic Fibrosis Foundation on May 5.
This morning, Vertex Pharmaceuticals announced the results from the Phase 3 clinical trials of ivacaftor (Kalydeco™) and lumacaftor (VX-809) in people with two copies of the F508del mutation.
Garry Shandling leaves a legacy gift to the Foundation in honor of his late brother, who had cystic fibrosis.